Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients

Video content above is prompted by the following:

• How do the treatment options evolve as a child ages?
• FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
• How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
• Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.